Search results for " gastrointestinal stromal tumor"

showing 9 items of 9 documents

Robotic Versus Laparoscopic Gastric Resection for Primary Gastrointestinal Stromal Tumors5 cm: A Size-Matched and Location-Matched Comparison.

2017

This study compared robotic (RR) and laparoscopic resection (LR) for primary gastrointestinal stromal tumors (GISTs) of the stomach >5 cm. Twelve consecutive patients who underwent RR from 2012 to 2015 were matched for tumor size and location with 24 patients who underwent LR from 2000 to 2012. The median tumor size was 7.1 cm (range, 5.5 to 11.5). GISTs were resected by wedge resection (91.7%) or distal gastrectomy. The median RR operative time was longer than that of LR (162.5 vs. 130 min, respectively; P=0.004). Only 1 LR patient required conversion. The time to flatus and hospital stay were similar between groups. Overall, 3 patients developed minor postoperative complications that w…

AdultMalemedicine.medical_specialtyStromal cellGastrointestinal Stromal TumorsOperative TimeBlood Loss Surgical030230 surgeryRobotic gastric resectionRisk Assessment03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRobotic Surgical ProceduresStomach Neoplasmslaparoscopic gastric resectionmedicineHumansLaparoscopic resectionGastric resectionUltrasonography InterventionalAgedAged 80 and overTumor sizebusiness.industryStomachIncidence (epidemiology)Length of StayMiddle AgedSurgerySettore MED/18 - Chirurgia Generalemedicine.anatomical_structureTreatment OutcomeSurgery Computer-Assisted030220 oncology & carcinogenesisCosts and Cost AnalysisOperative timeSurgeryFemaleLaparoscopybusinessprimary gastrointestinal stromal tumorGISTWedge resection (lung)Surgical laparoscopy, endoscopypercutaneous techniques
researchProduct

Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).

2019

11032 Background: GISTs are the most common mesenchymal tumors of the digestive tract. As of recent, new links are being made between GISTS and secondary malignancies. However, whether the coexistence of GISTs with other tumors is stochastic, or the result of related pathogenetic mechanisms is still unknown. Methods: We retrospectively reviewed clinical and molecular features from all GIST patients with second tumors treated in seven Italian GIST reference centers. Qualitative variables were compared using the Fisher exact test. Results: Clinical data of 184 patients with diagnosis of GIST were evaluated. Median age at diagnosis was 66 years, KIT exon 11 resulted the most frequent mutation…

Cancer ResearchPathologymedicine.medical_specialtyOncologybusiness.industryMesenchymal stem cellmedicineGIST - Gastrointestinal stromal tumorDigestive tractIn patientbusinessneoplasmsdigestive system diseasesJournal of Clinical Oncology
researchProduct

Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers

2015

Background: Long Non-coding RNAs (lncRNA) are emerging as essential regulators of genetic and epigenetic networks, and their deregulation may underlie complex diseases, such as carcinogenesis. Several studies have described lncRNAs alterations in patients with solid tumors. In particular, in Gastrointestinal Stromal Tumors (GIST), upregulation of HOTAIR has been associated with aggressiveness, metastasis, and poor patients’ survival. In order to gain more detailed insight on the molecular role of lncRNAs in GIST, we analyzed in vivo the expression levels of lncRNAs H19 and MALAT1 in surgically resected patients. Material and Methods: The expression of the lnc-RNAs H19 and MALAT1 was evaluat…

Long non coding RNAs Gastrointestinal Stromal Tumors prognostic/predictive biomarkers
researchProduct

Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors

2021

To investigate the correlation between CT imaging features and risk stratification of gastrointestinal stromal tumors (GISTs), prediction of mutation status, and prognosis. This retrospective dual-institution study included patients with pathologically proven GISTs meeting the following criteria: (i) preoperative contrast-enhanced CT performed between 2008 and 2019; (ii) no treatments before imaging; (iii) available pathological analysis. Tumor risk stratification was determined according to the National Institutes of Health (NIH) 2008 criteria. Two readers evaluated the CT features, including enhancement patterns and tumor characteristics in a blinded fashion. The differences in distributi…

Malemedicine.medical_specialtyMultivariate analysisGastrointestinal Stromal TumorsPopulationX-ray computedRisk Assessment030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingProgression-free survivaleducationPathologicalTomographySurvival analysisGastrointestinal stromal tumors; Mutation; Progression-free survival; Survival analysis; Tomography X-ray computed; Aged; Female; Humans; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Risk Assessment; Tomography X-Ray Computed; Gastrointestinal Stromal TumorsNeuroradiologyAgedRetrospective Studieseducation.field_of_studybusiness.industryProportional hazards modelTomography X-ray computedHazard ratioProgression-free survivalGeneral MedicineSurvival analysisMiddle AgedPrognosis030220 oncology & carcinogenesisMutationFemaleRadiologyGastrointestinal stromal tumors Mutation Progression-free survival Survival analysis Tomography X-ray computedbusiness
researchProduct

Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).

2020

e23518 Background: In patients with GIST, literature reports a risk of second primary tumors between 4.5% and 33% with different distribution in the worldwide. The network of 7 italian EURACAN centers has collected clinical and molecular features of GIST patients with second primary tumors. Methods: We reviewed the clinical characteristics of 201 patients with GIST and second primary tumors in order to evaluate association between risk of dead and each possible factor, using Kaplan meier curve, log-rank test and Cox model for Hazard Ratio and it’s interval Confidence 95% estimation. Furthermore, NGS analysis ( 56 gene onco panel) in 72 patients with GIST was performed. Results: On the basi…

OncologyCancer Researchmedicine.medical_specialtyGiSTbusiness.industryGIST - Gastrointestinal stromal tumorSecond primary cancerdigestive system diseasesOncologyInternal medicinemedicineIn patientbusinessneoplasmsJournal of Clinical Oncology
researchProduct

Gastrointestinal stromal tumors (GISTs): Focus on histopathological diagnosis and biomolecular features

2007

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract that are believed to originate from a neoplastic transformation of the intestinal pacemaker cells (interstitial cells of Cajal) normally found in the bowel wall or their precursors. Although the microscopic features have been known for a long time, the defining characteristic of GIST is the presence of the cell-surface antigen CD117 (KIT), which is demonstrated by immunohistochemistry. KIT, which is a growth factor transmembrane receptor, is the product of the proto-oncogene c-kit (chromosome 4). Surgical removal remains the only curative treatment for patients with GISTs. Tumor size, mitotic index,…

Pathologymedicine.medical_specialtyGastrointestinal Stromal TumorsPDGFRAProto-Oncogene MasHumansMedicineGastrointestinal stromal tumors; Histopathological diagnosis; Molecular biology; Novel therapies; Drug Resistance Neoplasm; Gastrointestinal Stromal Tumors; Humans; Hematology; OncologyNeoplastic transformationGastrointestinal stromal tumors (GISTs)neoplasmsbiologyGiSTbusiness.industryCD117SunitinibImatinibHematologymedicine.diseasedigestive system diseasesImatinib mesylateOncologyDrug Resistance Neoplasmbiology.proteinCancer researchbusinessmedicine.drug
researchProduct

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

2021

Background Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt various dosing and interval schedules to counteract regorafenib-related adverse events and avoid treatment interruption. The aim of this real-world study was to investigate the efficacy and safety of personalized schedules of regorafenib in patients with metastatic GIST, in comparison with the standard schedule (160 mg daily, 3-weeks-on, 1-week-off). Patients and methods Institutional registries a…

Phenylurea CompoundOncologyCancer Researchmedicine.medical_specialtyScheduleStromal cellPyridinesGastrointestinal Stromal TumorsPyridinePersonalized treatmentchemical and pharmacologic phenomenaMultikinase inhibitorchemistry.chemical_compoundQuality of lifeRetrospective Studieimmune system diseaseshemic and lymphatic diseasesInternal medicineRegorafenibmedicineHumansOriginal ResearchRetrospective StudiesGiSTbusiness.industryPhenylurea Compoundstoxicityhemic and immune systemspersonalized treatmentdigestive system diseasesquality of lifeOncologychemistryregorafenibGIST; personalized treatment; quality of life; regorafenib; toxicity; Humans; Phenylurea Compounds; Pyridines; Retrospective Studies; Gastrointestinal Stromal TumorsbusinessHumanGISTESMO Open
researchProduct

Prognostic significance of standardized AgNOR analysis and Ki-67 immunostaining in gastrointestinal stromal tumors

2003

Abstract OBJECTIVE: To evaluate the prognostic utility of argyrophilic nucleolar organizer region (AgNOR) protein parameters and Ki-67-immunostained growth fraction (Ki-67 labelling index) and to correlate AgNORs with Ki-67 LI and the main clinicopathologic parameters in gastrointestinal stromal tumors (GISTs). STUDY DESIGN: On 55 patients with surgically excised GISTs, visualization and quantification of AgNORs were performed as specified in the guidelines of the Committee on AgNOR Quantification. RESULTS: AgNOR protein area (NORA) ≥5.28 μm2 was statistically associated with mitotic rate ≥5x10 high-power fields (hpfs) (P <.001) and presence of necrosis (P <.001); Ki-67 LI ≥9.69% was signif…

Prognostic significance of standardized AgNOR analysis and Ki-67 immunostaining in gastrointestinal stromal tumors
researchProduct

COULD THE ENDOSCOPIC RESECTION OF A LARGE RECTAL LEIOMYOMA BE AN EFFETCIVE AND SAFE TECHNIQUE?

2016

Summary. Rectal leiomyomas are a rare conditions, with low reported incidence in literature and constitute about 0.1% of rectal tumours; in fact rectal leiomyomas occur in approximately 1 out of 2000-3000 rectal tumors. We report on a patient with a 3 cm semi-pedunculated colonic leiomyoma, which was successfully removed by endoscopic polypectomy after normal saline-epinephrine submucosal injection. When we encounter a tumor during a colonoscopic examination, we usually evaluate the tumor carefully and perform an endoscopic resection when we judge it is appropriate. When a symptomatic smooth muscle tumors smaller than 2 cm are incidentally found on colonoscopy, surgical resection is unneces…

Settore MED/18 - Chirurgia GeneraleSettore MED/12 - Gastroenterologiarectal leiomyoma endoscopic resection gastrointestinal stromal tumor
researchProduct